Hui Liu1, Yunfei Xia, Nianji Cui. 1. Department of Radiotherapy, The Affiliated Tumor Hospital of Sun-Yet-Sen University, Guangzhou, China.
Abstract
BACKGROUND AND PURPOSE: To determine the influence of diabetes mellitus on stages and long-term outcomes among patients with nasopharyngeal cancer. MATERIAL AND METHODS: The study summarized 37 patients who were diagnosed as having diabetes mellitus and nasopharyngeal cancer and treated by radiotherapy between January 1999 and December 1999. With a median follow-up of 34.6 mo, we analyzed differences in RFS, MFS, DFS, and OS between the diabetes and the non-diabetes group. RESULTS: 37 patients were involved in our study. According to the Chinese Fuzhou staging system for NPC, which was modified in 1992, 2 patients belong to stage I, 9 stage II, 17 stage III, and 6 stage IV. The 4-yr RFS of diabetes group and non-diabetes group was 52.1% vs 68.2%, the 4-yr MFS was 73.0% vs 72.0%, the 4-yr DFS was 35.1% vs 65.1%, and the OS was 67.6% vs 75.7%. The Wilcoxon (Gehan) test showed there was no significant difference between the two groups of RFS, MFS, and OS, while the diabetes group had a worse DFS than non-diabetes group (Wilcoxon p = 0.0047). CONCLUSIONS: Patients with diabetes had a worse DFS than non-diabetes, but statistic tests did not show significant differences in RFS, MFS, and OS; further studies should be continue to find out the results in the future.
BACKGROUND AND PURPOSE: To determine the influence of diabetes mellitus on stages and long-term outcomes among patients with nasopharyngeal cancer. MATERIAL AND METHODS: The study summarized 37 patients who were diagnosed as having diabetes mellitus and nasopharyngeal cancer and treated by radiotherapy between January 1999 and December 1999. With a median follow-up of 34.6 mo, we analyzed differences in RFS, MFS, DFS, and OS between the diabetes and the non-diabetes group. RESULTS: 37 patients were involved in our study. According to the Chinese Fuzhou staging system for NPC, which was modified in 1992, 2 patients belong to stage I, 9 stage II, 17 stage III, and 6 stage IV. The 4-yr RFS of diabetes group and non-diabetes group was 52.1% vs 68.2%, the 4-yr MFS was 73.0% vs 72.0%, the 4-yr DFS was 35.1% vs 65.1%, and the OS was 67.6% vs 75.7%. The Wilcoxon (Gehan) test showed there was no significant difference between the two groups of RFS, MFS, and OS, while the diabetes group had a worse DFS than non-diabetes group (Wilcoxon p = 0.0047). CONCLUSIONS:Patients with diabetes had a worse DFS than non-diabetes, but statistic tests did not show significant differences in RFS, MFS, and OS; further studies should be continue to find out the results in the future.
Authors: D J Tate; J R Adler; S D Chang; S Marquez; S M Eulau; W E Fee; H Pinto; D R Goffinet Journal: Int J Radiat Oncol Biol Phys Date: 1999-11-01 Impact factor: 7.038
Authors: Paul J Limburg; Kristin E Anderson; Trista W Johnson; David R Jacobs; Deann Lazovich; Ching-Ping Hong; Kristin K Nicodemus; Aaron R Folsom Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: H Toyoda; T Kumada; S Nakano; I Takeda; K Sugiyama; S Kiriyama; M Tanikawa; Y Sone; Y Hisanaga Journal: Cancer Date: 2001-03-01 Impact factor: 6.860
Authors: S Kono; S Honjo; I Todoroki; M Nishiwaki; H Hamada; H Nishikawa; H Koga; S Ogawa; K Nakagawa Journal: Cancer Causes Control Date: 1998-08 Impact factor: 2.506
Authors: Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati Journal: JAMA Date: 2008-12-17 Impact factor: 56.272